The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Class II and class III BRAF mutations in patients with advanced non-small cell lung cancer (NSCLC): Clinical characteristics, mutation patterns, and survival outcomes.
 
Anna Rasokat
No Relationships to Disclose
 
Anna Kron
No Relationships to Disclose
 
Lucia Nogova
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Janssen; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Novartis; Pfizer; Roche; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Dracen (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Celgene; Janssen; Novartis; Pfizer
 
Udo Siebolts
No Relationships to Disclose
 
Heather Scharpenseel
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen
 
Richard Riedel
Consulting or Advisory Role - Boehringer Ingelheim; Novartis
Travel, Accommodations, Expenses - Lilly; Loxo
 
Sebastian Yves Friedrich Michels
Honoraria - AstraZeneca; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Janssen; Novartis; Pfizer
 
Rieke Nila Fischer
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Janssen
 
Anna Eisert
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; MERCK
 
Darinka Prang
No Relationships to Disclose
 
Frank Beckers
No Relationships to Disclose
 
Kato Kambartel
No Relationships to Disclose
 
Britta Kaminsky
No Relationships to Disclose
 
Bernhard Schaaf
No Relationships to Disclose
 
Wolfgang Schulte
No Relationships to Disclose
 
Monika Heidi Serke
No Relationships to Disclose
 
Sabine Merkelbach-Bruse
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Novartis
 
Reinhard Buettner
Stock and Other Ownership Interests - Gnothis
Honoraria - Abbvie; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Illumina; Merck Serono; MSD; Novartis; Pfizer; Qiagen; Roche
Research Funding - Roche (Inst)
 
Juergen Wolf
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Janssen; Lilly; Loxo; Loxo/Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Nuvalent, Inc.; Pfizer; Roche; Seagen; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Ignyta; Janssen; Lilly; Loxo/Lilly; Merck; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Roche; Seagen; Takeda
Research Funding - Bristol-Myers Squibb; Janssen; Novartis; Pfizer
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Janssen; Merck; Mirati Therapeutics; Novartis; Pfizer; Sanofi
 
Matthias Scheffler
Honoraria - Amgen; AstraZeneca/Daiichi Sankyo; Boehringer Ingelheim; Novartis; Pfizer; Roche; Siemens Healthineers; Takeda
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Janssen Oncology; Novartis; Pfizer; Roche; Sanofi/Aventis; Takeda
Research Funding - Amgen (Inst); BMS GmbH & Co. KG (Inst); Dracen (Inst); Janssen (Inst); Novartis (Inst); Siemens Healthineers (Inst)
Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim; Janssen; Pfizer